Juraj Stanik1, Martina Skopkova2, Katarina Brennerova3, Daniel Danis2, Monika Rosolankova4, Anna Salingova5, Vladimir Bzduch3, Iwar Klimes2, Daniela Gasperikova6. 1. First Department of Pediatrics, Medical Faculty of Comenius University and Children Faculty Hospital, Limbova 1, 833 40 Bratislava, Slovakia; DIABGENE Laboratory, Institute of Experimental Endocrinology, Biomedical Research Center SAS, Dubravska cesta 9, 845 05 Bratislava, Slovakia. 2. DIABGENE Laboratory, Institute of Experimental Endocrinology, Biomedical Research Center SAS, Dubravska cesta 9, 845 05 Bratislava, Slovakia. 3. First Department of Pediatrics, Medical Faculty of Comenius University and Children Faculty Hospital, Limbova 1, 833 40 Bratislava, Slovakia. 4. Department of Intensive Care in Neonatology, Medical Faculty of Comenius University and Children Faculty Hospital, Limbova 1, 833 40 Bratislava, Slovakia. 5. Department of Laboratory Medicine, Children Faculty Hospital, Limbova 1, 833 40 Bratislava, Slovakia. 6. DIABGENE Laboratory, Institute of Experimental Endocrinology, Biomedical Research Center SAS, Dubravska cesta 9, 845 05 Bratislava, Slovakia. Electronic address: daniela.gasperikova@savba.sk.
Abstract
AIM: Congenital hyperinsulinism (CHI) and glycogen storage disease (glycogenosis) are both causing hypoglycemia during infancy, but with different additional clinical features and therapeutic approach. We aimed to identify a genetic cause in a child with an ambiguous phenotype. METHODS AND RESULTS: We present a child with hyperinsulinemic hypoglycemia, physiological 3-OH butyrate, increased triglyceride serum levels, increased level of glycogen in erythrocytes, increased liver transaminases, and increased echogenicity on liver ultrasonography. As both parents of the proband were referred as healthy, we raised a clinical suspicion on glycogenosis with recessive inheritance. However, whole exome sequencing revealed no mutation in genes causing glycogenosis, but a novel heterozygous variant LRG_483t1: c.427-1G>A in the HNF4A gene was identified. Aberrant splicing resulting in in-frame deletion c.429_476del, p.(T144_I159del) was confirmed by sequencing of HNF4A transcripts reverse-transcribed from whole blood RNA. The same variant was found in five of eight tested family relatives (one of them already had diabetes, two had prediabetes). With regard to the results of DNA analysis, we added diazoxide to the therapy. Consequently, the frequency and severity of hypoglycemia in the proband decreased. We have also recommended sulfonylurea treatment after diabetes onset in adult mutation carriers. CONCLUSIONS: We have identified a novel HNF4A gene mutation in our patient with CHI and glycogenosis-like phenotype. The proband and her family members benefited from the genetic testing by WES method and consequently personalized therapy. Nevertheless, the HNF4A gene testing may be considered in selected CHI cases with glycogenosis-like phenotype prior WES analysis.
AIM: Congenital hyperinsulinism (CHI) and glycogen storage disease (glycogenosis) are both causing hypoglycemia during infancy, but with different additional clinical features and therapeutic approach. We aimed to identify a genetic cause in a child with an ambiguous phenotype. METHODS AND RESULTS: We present a child with hyperinsulinemic hypoglycemia, physiological 3-OH butyrate, increased triglyceride serum levels, increased level of glycogen in erythrocytes, increased liver transaminases, and increased echogenicity on liver ultrasonography. As both parents of the proband were referred as healthy, we raised a clinical suspicion on glycogenosis with recessive inheritance. However, whole exome sequencing revealed no mutation in genes causing glycogenosis, but a novel heterozygous variant LRG_483t1: c.427-1G>A in the HNF4A gene was identified. Aberrant splicing resulting in in-frame deletion c.429_476del, p.(T144_I159del) was confirmed by sequencing of HNF4A transcripts reverse-transcribed from whole blood RNA. The same variant was found in five of eight tested family relatives (one of them already had diabetes, two had prediabetes). With regard to the results of DNA analysis, we added diazoxide to the therapy. Consequently, the frequency and severity of hypoglycemia in the proband decreased. We have also recommended sulfonylurea treatment after diabetes onset in adult mutation carriers. CONCLUSIONS: We have identified a novel HNF4A gene mutation in our patient with CHI and glycogenosis-like phenotype. The proband and her family members benefited from the genetic testing by WES method and consequently personalized therapy. Nevertheless, the HNF4A gene testing may be considered in selected CHI cases with glycogenosis-like phenotype prior WES analysis.
Authors: Arianna Maiorana; Francesca Romana Lepri; Antonio Novelli; Carlo Dionisi-Vici Journal: Front Endocrinol (Lausanne) Date: 2022-03-29 Impact factor: 5.555
Authors: Sara Jane Cromer; Aluma Chovel Sella; Emily Rosenberg; Kevin Scully; Marie McDonnell; Ana Paula Abreu; Michelle Weil; Sarah N Bernstein; Maryanne Quinn; Camille Powe; Deborah M Mitchell; Miriam S Udler Journal: AACE Clin Case Rep Date: 2022-08-08
Authors: Hadley Stevens Smith; J Michael Swint; Seema R Lalani; Jose-Miguel Yamal; Marcia C de Oliveira Otto; Stephan Castellanos; Amy Taylor; Brendan H Lee; Heidi V Russell Journal: Genet Med Date: 2018-05-14 Impact factor: 8.822
Authors: J Hulín; M Škopková; T Valkovičová; S Mikulajová; M Rosoľanková; P Papcun; D Gašperíková; J Staník Journal: Physiol Res Date: 2020-11-02 Impact factor: 1.881